CLOS
NTGN

Compagnie Lombard Odier SCmA’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-100
Closed -$560 – 618
2019
Q1 		$1K Buy
+100
New +$524 ﹤0.01% 569

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Compagnie Lombard Odier SCmA's NTGN Position: Q2 2019 in Review

Compagnie Lombard Odier SCmA sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2019, closing a stake of 100 shares — an estimated $560 sold.

Compagnie Lombard Odier SCmA first reported a position in NTGN in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 51 funds tracked by Wall St. Rank hold NTGN as of Q2 2019.

  • Compagnie Lombard Odier SCmA reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 100 Neon Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $560.
  • Compagnie Lombard Odier SCmA first reported a position in Neon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's Neon Therapeutics, Inc. Common Stock position peaked at $1K in Q1 2019.
  • 51 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2019, filed 14 Aug 2019.